BURLINGTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in four upcoming investor conferences.
2025 Wells Fargo Healthcare Conference
Wednesday, September 3, 2025
Encore Boston Harbor, Everett, MA
Dorian LeBlanc, CFO, will present at 1:30 PM ET
Cantor Global Healthcare Conference
Thursday, September 4, 2025
InterContinental New York Barclay Hotel, New York, NY
Dorian LeBlanc, CFO, will present at 10:55 AM ET
Morgan Stanley 23rd Annual Global Healthcare Conference
Tuesday, September 9, 2025
Sheraton New York Times Square, New York, NY
Dorian LeBlanc, CFO, will present at 3:20 PM ET
Barrington Research Fall Investment Conference (Virtual)
Tuesday, September 16, 2025
Dorian LeBlanc, CFO, time to be announced
About LeMaitre
LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. For more information about the Company, please visit www.lemaitre.com.
LeMaitre is a registered trademark of LeMaitre Vascular, Inc.
Last Trade: | US$94.48 |
Daily Change: | -0.54 -0.57 |
Daily Volume: | 91,004 |
Market Cap: | US$2.140B |
August 05, 2025 May 05, 2025 May 01, 2025 April 01, 2025 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load